Sponsored

Imugene (ASX: IMU) welcomes FDA IND transfer of azer-cel

September 28, 2023 11:11 AM AEST | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • The US FDA has transferred the IND application for allogenic CD19 CAR T azer-cel to Imugene.
  • Imugene had inked an agreement with Precision for azer-cel in August 2023.
  • Multi-centre Phase 1b study involving azer-cel is progressing.

In a significant development, the US Food and Drug Administration (FDA) has transferred the Investigational New Drug (IND) application for allogenic CD19 CAR T azer-cel (azercabtagene zapreleucel) to Imugene Limited (ASX: IMU).

Precision Biosciences Inc. (NASDAQ GS: DTIL) earlier held the application. Read more

The latest development follows the acquisition of an exclusive worldwide licence to azer-cel by Imugene in August.

 

 Data source: Company update

Share performance of IMU

IMU shares traded at AU$0.051 apiece, up 2%, at the time of writing on 28 September 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.